Gilgamesh Pharma (Gilgamesh Pharmaceuticals, Inc.) is a New York based clinical-stage neuroscience company founded in 2019 that develops rapid-acting, next-generation therapeutics for psychiatric and substance use disorders. Its discovery and translational platform combines medicinal chemistry, neurocircuitry science, electrophysiology and machine learning to identify new chemical entities, and its pipeline spans short-acting 5-HT2A receptor agonists, NMDA receptor antagonists, non-hallucinogenic neuroplastogens, cardiac-safe ibogaine analogs and M1/M4 muscarinic programs. Lead assets include bretisilocin (GM-2505), acquired by AbbVie in August 2025, and blixeprodil (GM-1020), an orally bioavailable NMDAR antagonist in Phase 2 for major depressive disorder. Gilgamesh is a drug developer, not a software vendor: it publishes no developer program, public API, SDK or machine-readable specification of any kind.
Gilgamesh Pharma is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Life Sciences, and Neuroscience.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: gilgamesh-pharma
name: Gilgamesh Pharma
description: 'Gilgamesh Pharma (Gilgamesh Pharmaceuticals, Inc.) is a New York based clinical-stage neuroscience company founded
in 2019 that develops rapid-acting, next-generation therapeutics for psychiatric and substance use disorders. Its discovery
and translational platform combines medicinal chemistry, neurocircuitry science, electrophysiology and machine learning
to identify new chemical entities, and its pipeline spans short-acting 5-HT2A receptor agonists, NMDA receptor antagonists,
non-hallucinogenic neuroplastogens, cardiac-safe ibogaine analogs and M1/M4 muscarinic programs. Lead assets include bretisilocin
(GM-2505), acquired by AbbVie in August 2025, and blixeprodil (GM-1020), an orally bioavailable NMDAR antagonist in Phase
2 for major depressive disorder. Gilgamesh is a drug developer, not a software vendor: it publishes no developer program,
public API, SDK or machine-readable specification of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/gilgamesh-pharma/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
specificationVersion: '0.20'
created: '2026-08-21'
modified: '2026-08-21'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Neuroscience
- Mental Health
- Clinical Trials
- Drug Discovery
- Health
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/gilgamesh-pharma-domain-security.yml
- type: Website
url: https://www.gilgameshpharmaceutical.com/
- type: LinkedIn
url: https://www.linkedin.com/company/gilgamesh-pharmaceuticals/
- type: Twitter
url: https://twitter.com/gilgameshrx
- type: PrivacyPolicy
url: https://mcusercontent.com/6c3f21fb747d330b7d588cc87/files/e79eefcc-bae9-6748-dc85-17d889fdb1af/Gilgamesh_Privacy_and_Expanded_Access_Policy_08.14.26.pdf
- type: Listing
url: https://forgeglobal.com/gilgamesh-pharma_stock/
x-enrichment:
date: '2026-08-21'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Gilgamesh Pharma is a clinical-stage drug developer whose entire web presence is a single static marketing page
on tiiny.host; /developers, /api, /docs, /openapi.json, /graphql, /llms.txt and every /.well-known/ path all return the
site's own 404, and the company ships molecules (bretisilocin, blixeprodil) rather than software, so there is no API to
publish.
evidence:
- url: https://www.gilgameshpharmaceutical.com/
status: 200
- url: https://www.gilgameshpharmaceutical.com/developers
status: 404
- url: https://www.gilgameshpharmaceutical.com/openapi.json
status: 404
- url: https://www.gilgameshpharmaceutical.com/.well-known/agent-card.json
status: 404
checked: '2026-08-21'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →